People: Geron Corp (GERN.OQ)

GERN.OQ on NASDAQ Stock Exchange Global Select Market

3.96USD
4 May 2015
Change (% chg)

$0.03 (+0.76%)
Prev Close
$3.93
Open
$3.93
Day's High
$4.07
Day's Low
$3.91
Volume
602,543
Avg. Vol
853,230
52-wk High
$4.48
52-wk Low
$1.60

Search Stocks

Bradbury, Daniel 

Mr. Daniel M. Bradbury is an Independent Director of Geron Corp., Daniel M. Bradbury has served as a director of Geron since September 2012. He also serves as a member of the boards of directors of Illumina, Inc., a manufacturer of life-science tools and integrated systems for the analysis of genetic variation and biological function; Corcept Therapeutics, a company focused on the discovery and development of drugs that regulate the effects of cortisol; BioCon Ltd., a company focused on reducing therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases; and BioMed Realty, a real estate investment trust focused on providing real estate to the life science industry, as well as being a member of the board of trustees of the Keck Graduate Institute. He also serves on the University of California San Diego, Rady School of Management’s Advisory Council, Investor Growth Capital Advisory Board and the BioMed Ventures Advisory Committee. Mr. Bradbury served as Chief Executive Officer of Amylin Pharmaceuticals, Inc., a biopharmaceutical company focused on diabetes and metabolic disorders, from March 2007 until its acquisition by Bristol-Myers Squibb Company in August 2012. Mr. Bradbury served as Amylin’s President from June 2006 until March 2007, as Chief Operating Officer from June 2003 until June 2006, as Executive Vice President from June 2000 until June 2003 and in other positions in corporate development and marketing from 1994 until 2000. In addition, Mr. Bradbury served as a member of the board of directors of Amylin from June 2006 until August 2012. Prior to joining Amylin, he spent ten years at SmithKline Beecham Pharmaceuticals, a pharmaceutical company, holding a number of sales and marketing positions. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Hoyoung Huh

--

John Scarlett

6,071,000

Olivia Bloom

2,036,260

Stephen Rosenfield

1,956,810

Andrew Grethlein

2,079,820

Melissa Kelly Behrs

2,042,560
As Of  30 Dec 2014
Search Stocks